Many epidemiologic studies have shown that the exposure to high external radiation doses increases thyroid neoplastic frequency, especially when given during childhood or adolescence. The use of
radioprotective drugs may decrease the damage caused by
radiation therapy and therefore could be useful to prevent the development of thyroid
tumors. The aim of this study was to investigate the possible application of
6-propyl-2-thiouracil (PTU) as a radioprotector in the thyroid gland. Rat thyroid epithelial cells (FRTL-5) were exposed to different doses of γ irradiation with or without the addition of PTU,
methimazole (MMI),
reduced glutathione (GSH) and
perchlorate (KClO4). Radiation response was analyzed by clonogenic survival assay.
Cyclic AMP (cAMP) levels were measured by radioimmunoassay (RIA). Apoptosis was quantified by nuclear cell morphology and
caspase 3 activity assays. Intracellular
reactive oxygen species (ROS) levels were measured using the
fluorescent dye 2',7'-dichlorofluorescein-diacetate.
Catalase,
superoxide dismutase and
glutathione peroxidase activities were also determined. Pretreatment with PTU, MMI and GSH prior to irradiation significantly increased the surviving cell fraction (SF) at 2 Gy (P < 0.05), while no effect was observed with KClO4. An increase in extracellular levels of cAMP was found only in PTU treated cells in a dose and time-dependent manner. Cells incubated with agents that stimulate cAMP (
forskolin and dibutyril cAMP) mimicked the effect of PTU on SF. Moreover, pretreatment with the inhibitor of
protein kinase A,
H-89, abolished the radioprotective effect of PTU. PTU treatment diminished radiation-induced apoptosis and protected cells against radiation-induced ROS elevation and suppression of the
antioxidant enzyme's activity. PTU was found to radioprotect normal thyroid cells through cAMP elevation and reduction in both apoptosis and radiation-induced oxidative stress damage.